Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis

Metabolic dysfunction–associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.1 Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments2 and could serve as an option for patients with MASH. Few studies have examined the efficacy of GLP-1 receptor agonists in MASH. In a phase 2 trial, treatment with semaglutide — a GLP-1 receptor agonist — led to resolution of steatohepatitis in 40 to 59% of patients but fell short of showing a significant reduction in . . .